Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Vilnius University
- Enrollment
- 280
- Locations
- 1
- Primary Endpoint
- To measure the levels of heat shock proteins in serum and plasma in acute severe pancreatitis settings
Study Overview
Brief Summary
To investigate the role of Heat Shock Proteins in the mechanism of acute severe pancreatitis. In addition to test the potential treatment target of acute pancreatitis.
All patients who present with clinical symptoms of acute pancreatitis are evaluated for the enrollment of the study.
Detailed Description
All patients with acute pancreatitis are evaluated according to modified Atlanta classification acute pancreatitis severity scores.
Blood serum, urine and DNA samples are collected from all patients presented on admission, after 24 hours, 48 hours, 72 hours.
CT is performed in al patients to evaluate necrosis of pancreas Day 5-7 since hospital admission. If necrosis is not present follow-up is stopped.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 100 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •no prior diagnosis of acute pancreatitis
- •admission to the hospital within 2 days since the clinical symptoms
- •confirmed diagnosis of acute pancreatitis
Exclusion Criteria
- •chronic pancreatitis
- •pancreatic cancer
Outcomes
Primary Outcomes
To measure the levels of heat shock proteins in serum and plasma in acute severe pancreatitis settings
Time Frame: 2 years
Different molecular weight Heat Shock proteins role while developing acute pancreatitis.
Secondary Outcomes
- To measure pancreas cells activity while applying Heat Shock Protein inhibitors(2 years)
Investigators
Aiste Gulla
Senior surgery resident
Vilnius University